Month: February 2026

Multisystem Inflammatory Syndrome in Children (Pediatric)

It’s a rare but serious inflammatory response, most commonly seen after a COVID-19 infection.

What it is:

An overactive immune response

Causes widespread inflammation affecting multiple organs

Common features:

Persistent fever

GI symptoms (abdominal pain, vomiting, diarrhea)

Rash, red eyes, swollen lips/hands

Heart involvement (myocarditis, low blood pressure)

Fatigue, headache

Timing:

Usually appears 2–6 weeks after a viral infection (classically COVID-19)

Treatment:

Hospital care
IVIG, steroids, anti-inflammatory meds

Most kids recover well with early treatment

If this is about a specific child or symptoms, I can explain warning signs, how it’s diagnosed, or how it differs from Kawasaki disease.

Gotcha — here’s a DM-level (doctor/medical) clinical note on MIS-C (Multisystem Inflammatory Syndrome in Children), written in a professional charting style.

Diagnosis:

Multisystem Inflammatory Syndrome in Children (MIS-C)

Definition:

MIS-C is a post-infectious hyperinflammatory syndrome occurring in pediatric patients, most commonly following SARS-CoV-2 infection. It is characterized by persistent fever, systemic inflammation, and involvement of two or more organ systems.

Epidemiology:

Typically presents in children and adolescents weeks after acute or asymptomatic COVID-19 infection. Incidence is rare but clinically significant due to potential cardiovascular involvement.

Pathophysiology:

Believed to be an immune-mediated response rather than direct viral injury. Dysregulated immune activation leads to cytokine release, endothelial dysfunction, and multisystem inflammation.

Clinical Presentation:

Persistent fever (>38.0°C, ≥24 hours)
Gastrointestinal symptoms (abdominal pain, vomiting, diarrhea)
Mucocutaneous findings (rash, conjunctival injection, strawberry tongue, swollen extremities)
Cardiovascular involvement (myocarditis, depressed ejection fraction, hypotension, shock)
Neurologic symptoms (headache, altered mental status, irritability)
Respiratory symptoms may be minimal or absent

Laboratory Findings:

Elevated inflammatory markers (CRP, ESR, ferritin, procalcitonin)
Lymphopenia, thrombocytopenia
Elevated D-dimer, fibrinogen
Elevated cardiac markers (troponin, BNP/NT-proBNP)
Evidence of recent SARS-CoV-2 infection (PCR or serology)

Diagnosis:

Clinical diagnosis based on CDC/WHO criteria, requiring fever, laboratory evidence of inflammation, multisystem involvement, and temporal association with SARS-CoV-2 infection, with exclusion of alternative diagnoses.

Management:

Hospital admission; PICU if hemodynamically unstable
Immunomodulatory therapy: IVIG and systemic corticosteroids
Supportive care (fluids, vasopressors if indicated)
Anticoagulation in select cases
Cardiology consultation and echocardiographic monitoring

Prognosis:

With prompt recognition and treatment, prognosis is generally favorable. Most patients recover fully, though long-term cardiac follow-up is recommended.

Urinary Tract Infection (UTI) in Children — Introduction

Urinary tract infection (UTI) (outlink to CDC) is one of the most common serious bacterial infections in childhood and an important cause of fever, morbidity, and potential long-term renal damage. UTIs involve infection of the urinary system, including the bladder (cystitis) and kidneys (pyelonephritis). Early recognition and appropriate management are essential to prevent complications such as renal scarring, hypertension, and chronic kidney disease.

Epidemiology

UTIs occur in approximately 5–8% of girls and 1–2% of boys by 7 years of age. During infancy, UTIs are more common in boys, especially those who are uncircumcised. After the first year of life, girls are affected more frequently due to anatomical and behavioral factors.

Causative Agents

The most common causative organism is Escherichia coli, accounting for the majority of infections. Other pathogens include Klebsiella, Proteus, Enterococcus, and Pseudomonas aeruginosa, particularly in children with structural abnormalities or catheterization. Link to Genitourinary system MCQs

Risk factors and Presentation

Risk factors include vesicoureteral reflux, urinary tract obstruction, neurogenic bladder, constipation, poor perineal hygiene, and dysfunctional voiding. Clinical presentation varies with age: neonates and infants may present with nonspecific signs such as fever, poor feeding, vomiting, or irritability, whereas older children typically present with dysuria, frequency, urgency, abdominal pain, or flank pain.

Prevention

Because recurrent infections increase the risk of renal scarring, identifying children at risk and initiating preventive strategies — including behavioral measures and, when indicated, antibiotic prophylaxis — is an important component of pediatric care.

UTI Prophylaxis in Children

Drug	Dose (once daily unless stated)	Age suitability	When preferred	Important notes
Nitrofurantoin	1–2 mg/kg at bedtime	>1 month	First-line prophylaxis	Avoid if G6PD deficiency; may cause nausea
Trimethoprim-Sulfamethoxazole (TMP-SMX)	2 mg/kg (TMP component)	>2 months	Common first choice	Avoid in neonates; risk of Stevens-Johnson syndrome
Trimethoprim alone	2 mg/kg	>2 months	Alternative to TMP-SMX	Useful if sulfa allergy
Cephalexin	10–12 mg/kg	All ages	Infants & vesicoureteral reflux	Good safety profile
Amoxicillin	10–15 mg/kg	<2 months	Neonatal prophylaxis	Resistance common after infancy
Cefixime	2 mg/kg	>6 months	Resistant organisms	Used less commonly

---

Indications for UTI Prophylaxis

• Vesicoureteral reflux (Grade III–V)
• Recurrent febrile UTIs (≥2 in 6 months or ≥3/year)
• Obstructive uropathy awaiting surgery
• Neurogenic bladder
• After first febrile UTI in infants until evaluation complete

---

Duration

• Continue until:
  • VUR resolves or is surgically corrected
  • Child becomes toilet trained and infection-free
  • Specialist review recommends stopping

---

Key Clinical Points

✔ Give at bedtime for maximal bladder concentration
✔ Encourage hydration & regular voiding
✔ Treat constipation (important risk factor)
✔ Monitor for breakthrough infections and resistance

Treatment of UTI in Children

Empirical Antibiotic Therapy (Based on Clinical Type)

Clinical Type	Oral Antibiotics (Outpatient)	IV Antibiotics (Inpatient / Severe)	Duration
Simple cystitis (Afebrile UTI)	Nitrofurantoin 5–7 mg/kg/day ÷ 2 doses Cephalexin 50–100 mg/kg/day ÷ 3–4 doses TMP-SMX 8–10 mg/kg/day (TMP component) ÷ 2 doses	Usually not required	5–7 days
Febrile UTI / Acute pyelonephritis	Cefixime 8 mg/kg/day OD Amoxicillin-clavulanate 40–50 mg/kg/day ÷ 2–3 doses	Ceftriaxone 50–75 mg/kg OD Cefotaxime 150 mg/kg/day ÷ 3 doses Gentamicin 5–7 mg/kg OD	7–14 days
Neonatal UTI (<2 months)	Not preferred	Ampicillin + Gentamicin OR Cefotaxime	10–14 days
Complicated UTI / Toxic child	Not preferred	Ceftriaxone ± Amikacin Consider Piperacillin-Tazobactam if resistant	10–14 days

---

Organism-Specific Considerations

Organism	Preferred Drugs
Escherichia coli	Cephalosporins, Nitrofurantoin, TMP-SMX (if sensitive)
Proteus	Avoid Nitrofurantoin; use cephalosporins
Pseudomonas aeruginosa	Ceftazidime, Piperacillin-Tazobactam
Enterococcus	Ampicillin, Amoxicillin

---

Supportive Management

Measure	Details
Hydration	Encourage oral fluids
Antipyretics	Paracetamol / Ibuprofen
Treat constipation	Important to prevent recurrence
Follow-up culture	If no improvement in 48 hours
Imaging	RBUS after first febrile UTI (especially <2 years)

---

Important Clinical Points

✔ Send urine routine + culture before starting antibiotics
✔ Switch from IV to oral once clinically improved (24–48 hrs)
✔ Modify antibiotics according to culture sensitivity
✔ Admit if: toxic appearance, persistent vomiting, dehydration, neonate, poor follow-up